
|Videos|November 18, 2019
PARP Inhibition in Ovarian Cancer: BRCA-Mutated and Beyond
Ovarian Cancer
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
2
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
3
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
4
How Resting Immune Cells Could Be the Key to Fighting Prostate Cancer
5








































